



STATE MEDICAID P&T COMMITTEE MEETING
THURSDAY, March 17, 2011
7:00 a.m. to 8:30 a.m.
Cannon Health Building
Room 114



MINUTES

Committee Members Present:

Karen Gunning, PharmD.

Raymond Ward, M.D.

Michael Flynn, M.D.

Kort DeLost, R.Ph.

Brandon Jennings, PharmD.

Lisa Hulbert R.Ph.

Beth Johnson, R.Ph.

Ellie Brownstein, M.D.

Dept. of Health/Div. of Health Care Financing Staff Present:

Robyn Seely, PharmD.

Richard Sorenson, R.N.

Jennifer Zeleny, CPhT, MPH

Tim Morley, R.Ph.

University of Utah Drug Information Center Staff Present:

Gary Oderda, PharmD.

Other Individuals Present:

Esther Estes, Merck

Barry Scott, Merck

Carin Steinvoert, College of Pharmacy

Efrain Alton, Merck

Jonny Mears, Guest

Nathan Votrubek, U of U Hosp.

Meeting conducted by: Karen Gunning PharmD., Co-Chairperson.

-
1. Review and Approval of Minutes: Brandon Jennings moved to approve the minutes. Karen Gunning seconded the motion. The motion was unanimously approved by Dr. Ward, Karen Gunning, Beth Johnson, Lisa Hulbert, Kort DeLost, and Brandon Jennings.
 2. DUR Board Update: Robyn Seely addressed the Committee. In March, the DUR Board reviewed oral MS therapies, and added the indication of prevention of relapse of opioid dependence to the Vivitrol PA. Medicaid is looking into mutual exclusivity edits with opioids and Vivitrol.
 3. Hormone Replacement Therapy: Dr. Gary Oderda with the University of Utah College of Pharmacy addressed the Committee and presented research on the oral and transdermal estrogens and progestins.

Dr. Ward asked for clarification on the risk of breast cancer for compliant versus non-compliant patients.

Karen Gunning asked if there was enough evidence to support the inclusion of a gel product. The University felt that there was.

The Committee asked for clarification on the generic available column. Several of the columns were wrong based on Committee members' experience.

Dr. Ward asked for public comment. There were no public members wishing to comment.

The Committee asked if there were any head-to-head trials for cancer risk in transdermal versus oral. There were no trials. Karen stated that there is a perception that they are safer, even though there is really no evidence for it. The transdermal doses are much smaller than the oral doses. However, the same amount may be absorbed systemically due to the first pass effect.

Lisa Hulbert clarified that PCN Program doesn't cover patches.

Karen Gunning stated that the Committee does not have utilization data. This particular class is not too sensitive to want to avoid switching, except that it may overwhelm physicians and pharmacists. The Committee felt that it would be helpful to have utilization data for future meetings, but intended to craft a motion for this meeting in order to address not wanting to be disruptive. Lisa stated that Medicaid does consider utilization and disruption to providers when choosing a preferred product.

Karen asked if the University knew which gel products were available in pre-measured packets. This is due to concern of potential overdoses with other topical gel forms.

Brandon Jennings moved that there are no differences in safety and efficacy. The PDL needs at least one single and one combination product, and at least one single and one combination topical product. .

The Committee questioned the need for including a gel product on the PDL. They are all single entity with no generics. Kort thought that it may be necessary due to sensitivity to adhesives. Jennifer questioned whether or not adhesive sensitivity through PA. The Committee felt that could be appropriate.

The motion was re-stated and clarified that the topical single-entity estrogen product should include at least one patch, but could include a patch and a gel.

Dr. Brownstein seconded the motion. The motion was unanimously approved by Dr. Ward, Karen Gunning, Beth Johnson, Lisa Hulbert, Kort DeLost, Dr. Flynn, and Dr. Brownstein and Brandon Jennings

Next Meeting Set for Thursday, May 19, 2011

There will be no April meeting due to Spring Break

Meeting Adjourned.

Minutes prepared by Jennifer Zeleny